SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation
D Balashov, P Trakhtman, A Livshits… - … and Apheresis Science, 2021 - Elsevier
Immunocompromised patients, including HSCT recipients, may have a poor prognosis after
contracting COVID-19 due to the absence of a pathogen-specific adaptive immune
response. One of the possible options for severe COVID-19 treatment may be the
transfusion of hyperimmune SARS-CoV-2 convalescent plasma. A 9-month-old girl with
juvenile myelomonocytic leukemia received an HSCT from a haploidentical donor. On day+
99, during routine virologic monitoring, SARS-CoV-2 was detected without any clinical …
contracting COVID-19 due to the absence of a pathogen-specific adaptive immune
response. One of the possible options for severe COVID-19 treatment may be the
transfusion of hyperimmune SARS-CoV-2 convalescent plasma. A 9-month-old girl with
juvenile myelomonocytic leukemia received an HSCT from a haploidentical donor. On day+
99, during routine virologic monitoring, SARS-CoV-2 was detected without any clinical …